Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.

Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis. - Safety and efficacy of Tenofovir alafenamide (TAF)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034362

Enrollment

500

Registered

2018-10-05

Start date

2018-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B and cirrhosis

Interventions

vemlidy 25mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis B

Exclusion criteria

Exclusion criteria: 1.Patients who has allergy to this drugs. 2.Patients with severe kidney disease. 3.Patients who are taking Tenofovir. 4.Patients who are pregnant or breast-feeding. 5.Patients who are judged ineligible by atending physician.

Design outcomes

Primary

Measure	Time frame
The rates of negativity of hepatitis B surface antigen. The amount of reduction of hepatitis B surface antigen.	—

Countries

Japan

Contacts

Public ContactNorio Itokawa

Nippon Medical Chiba Hokusoh Hospital Department of gastroenterology

mid@mtc.biglobe.ne.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026